 |
|
Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection
Roy T. Steigbigel, M.D., David A. Cooper, M.D., D.Sc., Princy N. Kumar, M.D., Joseph E. Eron, M.D., Mauro Schechter, M.D., Ph.D., Martin Markowitz, M.D., Mona R. Loutfy, M.D., M.P.H., Jeffrey L. Lennox, M.D., Jose M. Gatell, M.D., Ph.D., Jurgen K. Rockstroh, M.D., Christine Katlama, M.D., Patrick Yeni, M.D., Adriano Lazzarin, M.D., Bonaventura Clotet, M.D., Jing Zhao, Ph.D., Joshua Chen, Ph.D., Desmond M. Ryan, B.S., Rand R. Rhodes, M.S., John A. Killar, M.S., Lucinda R. Gilde, B.S., Kim M. Strohmaier, B.S., Anne R. Meibohm, Ph.D., Michael D. Miller, Ph.D., Daria J. Hazuda, Ph.D., Michael L. Nessly, M.S., Mark J. DiNubile, M.D., Robin D. Isaacs, M.D., Bach-Yen Nguyen, M.D., and Hedy Teppler, M.D., for the BENCHMRK Study Teams*
N. Engl. J. Med. 2008 Jul 24; 359(4): 339-54
 Ver artículo |
|
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection
Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Teppler H, Nguyen BY; BENCHMRK Study Teams.
N. Engl. J. Med. 2008 Jul 24; 359(4): 355-65
Ver artículo |
|
Virologic Outcomesof Changing Enfuvirtide to Raltegravir in HIV-1 Patients Well Controlled on an Enfuvirtide Based Regimen: 24 Weeks Results of the CHEER Study
Towner W.,Klein D.,Followsbee S.,Yu K.,Kenizar H.,Horberg M.
Poster Number TUPEO 115 XVII International AIDS Conference. August 3-8 2008 Mexico City, MX
Ver artículo |
|
Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaque
Hazuda DJ, Young SD, Guare JP, et al.
Science. 2004;305(5683):528—532. Epub 8 July 2004.
Ver cita en PubMed |
|
Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes
Grobler JA, Stillmock K, Hu B, et al.
Proc Natl Acad Sci U S A. 2002;99(10):6661—6666. Epub 7 May 2002.
Ver cita en PubMed |
|
HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase
Espeseth AS, Felock P, Wolfe A, et al.
Proc Natl Acad Sci U S A. 2000;97(21):11244—11249.
Ver cita en PubMed |
|
A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase
Hazuda DJ, Anthony NJ, Gomez RP, et al.
Proc Natl Acad Sci U S A. 2004;101(31):11233—11238. Epub 26 July 2004.
Ver cita en PubMed |
|
Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells
Hazuda DJ, Felock P, Witmer M, et al.
Science. 2000;287(5453):646—650.
Ver cita en PubMed |
|
|
|
|
|
|
†Marca Registrada de Merck & Co., Inc., Whitehouse Station, NJ, EUA
|
|
|
